Novo Nordisk Sues Eli Lilly Over Obesity-Drug Advertising Claims
Novo says it's seeking a court order forcing Lilly to pull ads for its obesity drugs and run a corrective campaign. Here's what's actually being alleged.
By the GLP Semaglutide editorial team · Last updated August 7, 2026
Novo Nordisk says it has filed suit against Eli Lilly, accusing the company of false advertising in how it has marketed its obesity drugs against Novo's Wegovy and Wegovy pill. This is separate from Novo's ongoing litigation against compounding pharmacies covered elsewhere on this site — different defendant, different legal theory.
What Novo is asking for
According to reporting on the filing, Novo is seeking a court order requiring Lilly to withdraw the advertisements at issue and run a corrective advertising campaign, and says it plans to seek a preliminary injunction if Lilly doesn't remove the ads voluntarily.
The backdrop
The suit lands amid an intensifying competitive fight: Lilly has been gaining U.S. obesity-market share from Novo, a dynamic that showed up clearly in both companies' most recent quarterly earnings. Advertising claims about comparative effectiveness are a common flashpoint in pharma competition, but a lawsuit over them is a more aggressive step than the usual back-and-forth.
What happens next
Litigation timelines are unpredictable, and the specific ads and claims at issue matter more than the topline framing. Court filings, once available, are the authoritative source for the actual legal arguments on both sides — this article is based on early news coverage of the filing, not the complaint itself.
Primary sources